Introduction {#S1}
============

Today, tuberculosis (TB) remains a major threat worldwide than any other single infectious disease. Millions of people continue to fall sick with TB each year. Moreover, the increasing rates of drug-resistant TB (DR-TB) worldwide and the emergence of multidrug/extensively-drug resistant TB (MDR/XDR-TB), leading to a high mortality as well as the financial burden. Regarding cases, estimates of the burden of DR-TB have focused on MDR-TB, there were 457,560 people (range: 396,060--523,980) developed MDR-TB ([@B35]). Among cases of MDR-TB, 8.5% (*95%CI*: 6.2--11.0) were estimated to have XDR-TB ([@B35]).

MDR-TB patients ordinarily require 18 months of treatment with recommendatory second-line anti-TB drugs (SLD) that primarily include fluoroquinolones (FQ) and second-line injectable drugs (SLID). Similar to other anti-TB agents, the main mechanisms of *Mycobacterium tuberculosis* (*M. tuberculosis*) resistant to SLD rely on spontaneous chromosomal mutations. Associated-mutations in the fluroquinolone resistance-determining region (QRDR) of DNA gyrase-coding genes *gyrA* and *gyrB* turned out to be responsible for FQ resistance (FQ^r^) ([@B12]). The genetic determinants of SLID resistance (SLID^r^) are more complicated and suggested that being involved in three well-known genes. Cross-resistance between kanamycin (KAN), amikacin (AMK) and capreomycin (CAP) is thought to be associated with mutations in the16S rRNA gene *rrs*, specifically at position A1401G ([@B1]; [@B27]). Mutations in promoter region of *eis* gene, encoding an aminoglycoside acetyltransferase, caused low-level KAN resistance ([@B5]; [@B25]). CAP resistance has been correlated with mutations in *tlyA* gene, which encodes a putative 2′-*O*-methyltransferase (TlyA) ([@B15]; [@B33]).

Currently, little is known about mutation profiles of SLD resistance (SLD^r^) in clinical *M. tuberculosis* isolates in our area, the objectives of this study were to compare the sequencing data of SLD^r^ associated-genes (FQ for *gyrA* and *gyrB*, SLID for *rrs* region 1400, *eis* promoter and *tlyA*) with the phenotypic results by the traditional proportion method in 275 drug-resistant clinical *M. tuberculosis* isolates collected in Hebei, and to analyze the *M. tuberculosis* genetic diversity of SLD^r^-TB (covering FQ^r^-TB and SLID^r^-TB), and to elucidate transmission pattern by using Spoligotyping and 15-loci MIRU-VNTR typing.

Materials and Methods {#S2}
=====================

*M. tuberculosis* Isolates {#S2.SS1}
--------------------------

For the present study, we successfully recovered 257 clinical *M. tuberculosis* isolates. Isolates were obtained from sputum samples provided by confirmed pulmonary patients (167 males and 90 females; age range: 14--83 years; median age: 41 years; 146 new patients and 111 retreated patients) attending eight hospitals in Hebei over 1-year period (From January to December in 2014). One hundred pan-susceptible *M. tuberculosis* isolates served as negative control. [Figure 1](#F1){ref-type="fig"} shows the selection process of clinical *M. tuberculosis* isolates originated from Hebei Province.

![Flow chart and strains selection in this study.](fmicb-10-01838-g001){#F1}

Drug Susceptibility Testing {#S2.SS2}
---------------------------

Drug susceptibility testing against SLD was performed using conventional proportion method on Lowenstein-Jensen (L-J) medium (Celnovte-bio, Henan, China) cultured for 4 weeks ([@B34]), with the following break-out values: ofloxacin (OFX) 2 μg/mL; levofloxacin (LVX) 2 μg/mL; KAN 30 μg/mL; AMK 30 μg/mL, and CAP 40 μg/mL. Each DST was used *M. tuberculosis* H37Rv (ATC27294) as a reference control.

DNA Isolation, Amplification, and Sequencing {#S2.SS3}
--------------------------------------------

Genomic DNA extractions were re-suspended a loopful of bacilli in 200 uL of fast lysis buffer (Qiagen, Valencia, CA, United States) and heat inactivated at 80°C for 10 min, followed by centrifugation at 13,000 *g* for 5 min. All genes were chosen on the basis of documented association with resistance to SLD and included *gyrA* and *gyrB* for FQ and *rrs*, *eis* promoter, and *tlyA* for SLID. Primers and amplicon sizes are presented in the [Supplementary Table S1](#SD1){ref-type="supplementary-material"}. Each 20 μL PCR mixture was prepared as follows: 10 μL 2× Taq Master Mix (CWBOIO, Beijing, China), 1 μL of the forward and reverse 10 μM primers, 1 μL genomic DNA, and final 7 μL distilled H~2~O complement. PCR program for amplification were 5 min at 94°C, followed by 35 cycles of 30 s at 94°C, 30 s at 60°C, 30 s at 72°C, and a final extension 72°C for 10 min.

Sequencing services were provided by Tsingke Biological Technology company (TsingKe, Beijing, China). All the mutations were identified and aligned with the homologous sequences of the reference *M. tuberculosis* H37Rv strain (GenBank accession number NC_000962) using the BLASTN algorithm^[1](#footnote1){ref-type="fn"}^.

Genotyping {#S2.SS4}
----------

Spoligotyping was used to identify Beijing family as described previously by [@B18]. The direct repeat region was amplified with the primer pairs included DRa (5′-GGTTTTGGGTCTGACGAC-3′) and DRb (5′-CCGAGAGGGGACGGAAAC-3′). All PCR products were hybridized to a set of 43 oligonucleotide probes corresponding to each spacer that were covalently bound to a membrane. Spoligotypes in binary formats were matched with Spoldb.4.0 database^[2](#footnote2){ref-type="fn"}^, and applied the published rules for definition of Beijing family (hybridization to at least three of the spacers 35--43 in direct repeat region and absence of hybridization to spacers 1--34).

MIRU-VNTR typing method was based on 15-loci set, including Mtub04, ETRC, ETRD, MIRU40, MIRU10, MIRU16, Mtub21, QUB11b, ETRA, Mtub30, MIRU26, ETRE, Mtub39, QUB26, QUB4156, as previously reported ([@B31]; [@B22]). A phylogenetic tree was built using UPGMA algorithm at the web site MIRU-VNTR*plus*^[3](#footnote3){ref-type="fn"}^.

Definitions {#S2.SS5}
-----------

Based on the following definitions, we utilize these terms throughout the rest of this article. (i) Drug-resistant (DR): defined as resistance to at least one first- or second-line drug; (ii) Fluoroquinolones (FQ): defined as resistance to at least one OFX or LVX; (iii) Second-line injectable drugs (SLID): defined as resistance to at least one AMK, KAN, and CAP; (iv) Second-line anti-TB drugs (SLD): defined as resistance to at least one fluoroquinolones or second-line injectable drugs; (v) Multidrug-resistant (MDR): defined as resistance to at least two of the most effective anti-TB drugs, isoniazid and rifampin ([@B35]); (vi) Pre-extensively drug-resistant (Pre-XDR): defined as MDR resistance to either fluoroquinolones or second-line injectable drugs; (vii) Extensively drug-resistant (XDR): defined as MDR-TB plus resistance to a fluoroquinolone and at least one second-line injectable drug ([@B35]).

Data Analysis {#S2.SS6}
-------------

To assess the associations between variables (DST, mutations, and genotyping), the χ^2^ test, odds ratio (*OR*) and 95% confidence interval (*95%CI*) were calculated. And the Fishers' exact was used if any expected counts are less than 5. A *P*-value of \< 0.05 was considered statistically significant. All statistical data analyzed with SPSS version 22.0 (IBM SPSS, Chicago, IL, United States).

Resolution of Discrepant Results {#S2.SS7}
--------------------------------

When the results between DST and DNA sequencing were not consistent, two methods were used for repeated testing. If the duplicate result conflicted with the original data, a third round of testing was accepted as a final value.

Results {#S3}
=======

Strains Selection and Drug Resistance Patterns {#S3.SS1}
----------------------------------------------

Initially, a total of 316 DR isolates were re-cultured and finally only 257 eligible isolates were included in this study. The selection procedure of strains is shown in [Figure 1](#F1){ref-type="fig"}. A total 257 eligible isolates, 170 (170/257, 66.1%) isolates were resistant to isoniazid; 152 (152/257, 59.1%) to rifampicin; 74 (74/257, 28.8%) to ethambutol; and 176 (176/257, 56.8%) to streptomycin.

Among 257 DR isolates, 48.2% (124/257) were resistant to at least one of five SLD and the remaining 51.8% (133/257) were susceptible to all SLD. Of them, 37.7% (97/257) were FQ^r^ isolates and 24.5% (63/257) were SLID^r^ isolates. A total of 118 isolates (45.9%, 118/257) identified as MDR, of which 46 isolates (17.9%, 46/257) were Pre-XDR and 10.9% (28/257) were XDR. At the same time, there were 32.7% (84/257), 21.7% (56/257), 20.2% (52/257), 7.0% (18/257), and 6.2% (16/257) of 257 DR isolates were found to be resistant to OFX, LVX, KAN, AMK and CAP, respectively. Detailed profiles of 275 DR isolates against five SLD were summarized in [Table 1](#T1){ref-type="table"}.

###### 

Profiles of drug resistance to second-line drugs among the studied drug-resistant isolates.

  **DST patterns^a^**                **No. of isolates**   **Proportion (%)**
  ---------------------------------- --------------------- --------------------
  Mono-resistant                                           
  OFX                                24                    9.34
  LVX                                9                     3.5
  KAN                                20                    7.78
  AMK                                1                     0.39
  CAP                                2                     0.78
  Multi-resistant                                          
  OFX + LVX                          28                    10.89
  OFX + KAN                          8                     3.11
  OFX + AMK                          3                     1.17
  OFX + CAP                          3                     1.17
  LVX + CAP                          1                     0.39
  KAN + AMK                          2                     0.78
  KAN + CAP                          1                     0.39
  OFX + LVX + KAN                    8                     3.11
  OFX + KAN + AMK                    1                     0.39
  OFX + KAN + CAP                    1                     0.39
  OFX + AMK + CAP                    1                     0.39
  LVX + KAN + AMK                    2                     0.78
  KAN + AMP + CAP                    1                     0.39
  OFX + LVX + KAN + AMK              2                     0.78
  OFX + LVX + KAN + CAP              1                     0.39
  LVX + KAN + CAP + AMK              1                     0.39
  OFX + LVX + KAN + AMK + CAP        4                     1.56
  Susceptible to second-line drugs   133                   51.8

a

DST, drug susceptibility testing; OFX, ofloxacin; LVX, levofloxacin; KAN, kanamycin; AMK, amikacin; CAP, capreomycin.

Out of 84 OFX^r^ isolates, 43 isolates (44.3%, 43/97) were simultaneously resistant to LVX ([Figure 2A](#F2){ref-type="fig"}). Among 52 KAN^r^ isolates, 6 isolates were resistant to both AMK and CAP, the cross-resistance rate between KAN, AMK and CAP was 9.5% (6/64) ([Figure 2B](#F2){ref-type="fig"}). Compared with FQ^r^, there was significant difference in SLID^r^ (37.7 vs. 24.5%, 1.9 *OR*, *95%CI* \[1.3, 2.7\], *P* = 0.001), MDR (37.7 vs. 45.9%, 2.6 *OR*, *95%CI* \[1.8, 3.8\], *P* \< 0.001), Pre-XDR (37.7 vs. 17.9%, 0.4 *OR*, *95%CI* \[0.2, 0.5\], *P* \< 0.001) and XDR (37.7 vs. 10.9%, 0.2 *OR*, *95%CI* \[0.1, 0.3\], *P* \< 0.001) ([Figure 3](#F3){ref-type="fig"}). Detailed distribution of drug-resistant strains resistant to OFX, LVX, KAN, AMK and CAP as shown in [Supplementary Figure S1](#SD1){ref-type="supplementary-material"}.

![Analysis of phenotypic and genetic characterizations in different drug-resistance patterns. **(A)** Venn diagram of isolates identified from FQ group. The left circle shows any resistance to OFX, the right circle shows any resistance to LVX, the overlapping region shows isolates resistant to both OFX and LVX. **(B)** Venn diagram of isolates identified from SLID group. Each circles show any resistance to KAN, AMK, and CAP, respectively. The overlapping regions show isolates cross-resistant to the corresponding drugs. **(C)** The *gyrA* mutations were significantly associated with cross-resistance of FQ (4.13 *OR*, *95%CI* \[1.39, 12.23\], *P* = 0.009), resistance of FQ (45.63 OR, 95%CI \[20.73,100.42\], *P* \< 0.001), MDR (7.49 *OR*, *95%CI* \[4.09, 13.70\], *P* \< 0.001), Pre-XDR (10.81*OR*, *95%CI* \[5.10, 22.88\], *P* \< 0.001), and XDR (17.29 *OR*, *95%CI* \[5.76, 51.89\], *P* \< 0.001). **(D)** The *rrs* mutations were significantly associated with cross-resistance of SLID (3.17 *OR*, *95%CI* \[2.16, 4.64\], *P* = 0.002), resistance of SLID (9.23 *OR*, *95%CI* \[9.60, 88.98\], *P* \< 0.001), MDR (5.08 *OR*, *95%CI* \[1.98, 13.00\], *P* \< 0.001), and XDR (24.11 *OR*, *95%CI* \[9.35, 62.20\], *P* \< 0.001). ^\*^Indicates the difference is statistically significant (*P* \< 0.05).](fmicb-10-01838-g002){#F2}

![Distribution of drug-resistant strains resistant to different second-line drug group. ^a^Compared with XDR group, there was a significantly lower than FQ (0.20 *OR*, *95%CI* \[0.13, 0.32\], *P* \< 0.001), SLID (0.38 *OR*, *95%CI* \[0.23, 0.61\], *P* \< 0.001), Pre-XDR (0.56 *OR*, *95%CI* \[0.34, 0.93\], *P* = 0.024) and MDR (0.14 *OR*, *95%CI* \[0.09, 0.23\], *P* \< 0.001). ^b^Compared with Pre-XDR group, there was significantly lower than FQ (0.36 *OR*, *95%CI* \[0.24, 0.54\], *P* \< 0.001), and MDR (0.26 *OR*, *95%CI* \[0.17, 0.38\], *P* \< 0.001). ^c^Compared with MDR group, there was significantly higher than FQ (2.61 *OR*, *95%CI* \[1.80, 3.81\], *P* \< 0.001). ^d^Compared with SLID group, there was significantly lower than FQ (1.87 *OR*, *95%CI* \[1.27, 2.73\], *P* = 0.001).](fmicb-10-01838-g003){#F3}

Mutations in *gyrA* and *gyrB* {#S3.SS2}
------------------------------

It is known to that the main molecular mechanism of FQ^r^ was caused by mutations in the QRDR of DNA gyrase, which composed of GyrA and GyrB subunits, encoded by *gyrA* and *gyrB* genes, respectively. DNA sequencing results of these two genes from FQ^r^, FQ^s^ and pan-susceptible isolates were summarized in [Table 2](#T2){ref-type="table"}.

###### 

Analysis of the *gyrA* and *gyrB* mutations in resistant, sensitive to FQ and to pan-susceptible *M. tuberculosis* isolates.

  **Fluoroquinolones^a^**   ***gyrA*^b^**   ***gyrB***   **No. of isolates**                        
  ------------------------- --------------- ------------ --------------------- ------------ ------- ----
  R                         R               GCG269GTG    A90V                  WT           WT      9
                                            GCG269GTG    A90V                  AAC1496ACC   N499T   1
                                            GAC281GGC    D94G                  WT           WT      13
                                            GAC281GCC    D94A                  WT           WT      3
                                            GAC280TAC    D94Y                  WT           WT      3
                                            GAC280TAC    D94Y                  GCG1534GCA   A508A   1
                                            GAC280AAC    D94N                  WT           WT      7
                                            GAC265AAC    D89N                  WT           WT      1
                                            WT           WT                    GAC1381AAC   D461N   1
  R                         S               GCG269GTG    A90V                  WT           WT      7
                                            GAC281GGC    D94G                  WT           WT      7
                                            GAC281GGC    D94G                  CTG1324TTG   L442L   1
                                            GAC281GCC    D94A                  WT           WT      3
                                            GAC280TAC    D94Y                  WT           WT      2
                                            GAC280AAC    D94N                  WT           WT      4
                                            WT           WT                    GCG1511GTG   A504V   1
                                            WT           WT                    TCC1340TTC   S447F   1
                                            WT           WT                    GCG1534GCA   A508A   1
  S                         R               TCG271CCG    S91P                  WT           WT      2
                                            GCG269GTG    A90V                  WT           WT      5
                                            GAC281GGC    D94G                  WT           WT      2
                                            GAC280TAC    D94Y                  WT           WT      2
  S                         S               GCG269GTG    A90V                  WT           WT      2
                                            GAC281GGC    D94G                  WT           WT      2
                                            GAC281GCC    D94A                  WT           WT      5
                                            CGC318CGA    R106R                 WT           WT      1
                                            WT           WT                    GCG1534GCA   A508A   5
                                            WT           WT                    AAG1322AGG   K441R   1
                                            WT           WT                    TCC1340TAC   S447Y   1
  Pan-susceptible           GCG269GTG       A90V         WT                    WT           2       
                                            GAC281GGC    D94G                  WT           WT      1
                                            GAC281GCC    D94A                  WT           WT      1
                                            WT           WT                    GGT1307GTT   G436V   1

a

OFX, ofloxacin; LVX, levofloxacin; R, resistance; S, sensitivity.

b

WT, wild-type.

Of 97 FQ^r^ isolates, 73 isolates (73/97, 75.3%) carried mutations within *gyrA* gene, including codons 89, 90, 91, and 94. The most predominant mutation occurred at codon 94, with four different amino acid changes, D94G (23/97, 23.7%), D94A (6/97, 6.2%), D94Y (8/97, 8.2%), and D94N (11/97, 11.3%), which accounted for 49.5% (48/97) of FQ^r^ isolates. The A90V was the next most prevalent mutation, 22.7% (22/97) of isolates harbored this mutation. Besides, a single mutation in or near the QRDR of *gyrB* gene associated with FQ^r^ was detected in 4 isolates, including D461N (1/97, 1.0%), A504V (1/97, 1.0%), S447F (1/97, 1.0%) and A508A (1/97, 1.0%). Double mutations in both *gyrA* and *gyrB* were observed in three isolates, one with A90V and N499T mutation, one with D94Y and A508A mutation and one with D94G and L442L.

Of 160 FQ^s^ isolates, 17 isolates (17/160, 10.6%) displayed mutations within these two target fragments (*gyrA* and *gyrB*). Among them, the mutations within *gyrA* included A90V (2/160, 1.3%), D94G (2/160, 1.3%), D94A (5/160, 3.1%), and R106R (1/160, 0.6%) and mutations within *gyrB* were observed in 7 isolates with A508A (5/160, 3.1%), K441R (1/160, 0.6%), and S447Y (1/160, 0.6%).

Among 79 pan-susceptible isolates, 3 isolates each had mutations at codon 90 (A-V),94 (D-G), or 94 (D-A) in *gyrA* gene. Mutation at codon 436 (G-V) of *gyrB* gene was observed only one isolate.

Mutations in *rrs, eis* Promoter and *tlyA* {#S3.SS3}
-------------------------------------------

To determine the molecular basis of resistance to SLID, the *rrs*, *eis* promoter, and *tlyA* region were sequenced both in SLID^r^, SLID^s^, and pan-susceptible strains. [Table 3](#T3){ref-type="table"} showed the mutations in the 1400 region of *rrs*, *eis* promoter and *tlyA* as well as the corresponding resistance phenotypes.

###### 

Analysis of *rrs*, *eis* promoter and *tlyA* mutations in resistant, sensitive to SLID and to pan-susceptible *M. tuberculosis* isolates.

  **Second-line injectable drugs^a^**   ***rrs*^b^**   ***eis* promoter**   ***tlyA***   **No. of isolates**                       
  ------------------------------------- -------------- -------------------- ------------ --------------------- ----------- ------- ---
  R                                     R              R                    A1401G       WT                    WT          WT      6
  R                                     R              S                    A1401G       WT                    WT          WT      3
                                                                            WT           G (−10) A             WT          WT      1
  R                                     S              R                    A1401G       WT                    WT          WT      1
                                                                            WT           G (−10) A             WT          WT      1
  R                                     S              S                    A1401G       WT                    WT          WT      8
                                                                            T1491C       WT                    WT          WT      1
                                                                            A1499G       WT                    WT          WT      1
                                                                            WT           G (−10) A             WT          WT      1
                                                                            WT           C (−14) T             WT          WT      2
  S                                     R              S                    A1401G       WT                    WT          WT      2
                                                                            G1454A       WT                    WT          WT      1
  S                                     S              R                    A1401G       WT                    WT          WT      1
                                                                            WT           WT                    AAA205GAA   K69E    1
                                                                            WT           WT                    GCG356GAG   A119E   1
                                                                            WT           WT                    AAA567AAC   K189N   1
  S                                     S              S                    A1128G       WT                    WT          WT      1
                                                                            A1138G       WT                    WT          WT      1
                                                                            C1209T       WT                    WT          WT      1
                                                                            C1483T       WT                    WT          WT      1
  Pan-susceptible                       WT             G (−37) T            WT           WT                    1                   
                                                                            WT           WT                    GTG161GGG   V54G    1
                                                                            WT           WT                    ACC159ACT   T53T    1

a

KAN, kanamycin; AMK, amikacin; CAP, capreomycin; R, resistance; S, sensitivity.

b

WT, wild-type.

Of 63 SLID^r^ isolates, the most frequent mutation was the change from A to G at position 1401 of *rrs* gene, observed in 33.3% (21/63) of isolates. Three additional isolates displayed mutations at T1491C, G1454A, and A1499G in *rrs*. Mutations within the promoter region of *eis* included G (−10) A (3/63, 4.8%) and C (−14) T (2/63, 3.2%). Nevertheless, mutations in *tlyA* conferring amino acid substitutions K69E (1/63, 1.6%), A119E (1/63, 1.6%), and K189N (1/63, 1.6%), solely appeared in CAP^r^ isolates.

Of 193 SLID^s^ isolates, one isolate each of A1128G, A1138G, C1209T, and C1483T, all occurred in *rrs*. Furthermore, for *eis* promoter, a change from G to T at −37 was detected only one isolate.

Among 79 pan-susceptible isolates, none of mutations were tested by us, except that, two clinical isolates with mutations V54G and T53T in *tlyA*.

Association Between Gene Mutations and Phenotypes {#S3.SS4}
-------------------------------------------------

Among the 97 FQ^r^ isolates with *gyrA* mutations, 63.9% (62/97) were resistant to OFX and 50.5% (49/97) were resistant to LVX. As seen in [Figure 2C](#F2){ref-type="fig"}, strongly evidence showed that *gyrA* mutations were associated with the cross-resistance of FQ (4.1 *OR*, *95%CI* \[1.4, 12.2\], *P* = 0.009), FQ (45.6 *OR*, *95%CI* \[20.7, 100.4\], *P* \< 0.001), MDR (7.5 *OR*, *95%CI* \[4.1, 13.7\], *P* \< 0.001), Pre-XDR (10.8 *OR*, *95%CI* \[5.1, 22.9\], *P* \< 0.001), and XDR (17.3 *OR*, *95%CI* \[5.8, 51.9\], *P* \< 0.001). On the contrary, there was no significant correlation between FQ^r^ isolates with *gyrB* mutations (1.7 *OR*, *95%CI* \[0.6, 5.0\], *P* = 0.331) ([Table 4](#T4){ref-type="table"}).

###### 

Evaluation of phenotypic resistance of second-line anti-tuberculosis strains by mutations in second-line drug-resistant genes.

                                             **No. of isolates**             **Performance ^c^**                                                         
  ---------- ------------------------------- --------------------- ---- ---- --------------------- --------- -------------------- ------ ------- ------- ------
  FQ         *gyrA*                          73                    24   10   150                   \<0.001   46.0 (21.0,100.4)    75.2   94.0    88.0    86.2
             *gyrB*                          7                     90   7    153                   \<0.001   2.0 (1.0, 5.0)       7.2    96.0    50.0    63.0
             *gyrA, gyrB*                    77                    20   17   143                   0.331     32.4 (16.0, 65.4)    79.4   89.4    82.0    88.0
  SLID       *rrs*                           24                    39   4    190                   \<0.001   29.2 (10.0, 89.0)    38.1   98.0    86.0    83.0
             *eis* promoter                  5                     58   1    193                   0.004     17.0 (2.0, 145.3)    8.0    99.5    83.3    77.0
             *tlyA*                          3                     60   0    194                   0.014     1.0 (1.0, 1.0)       5.0    100.0   100.0   76.4
             *rrs*, *eis* promoter           29                    34   5    189                   \<0.001   32.2 (12.0, 89.1)    46.0   97.4    85.3    85.0
             *eis* promoter, *tlyA*          8                     55   1    193                   \<0.001   28.0 (3.4, 229.3)    13.0   99.5    89.0    78.0
             *rrs* and *tlyA*                27                    36   4    190                   \<0.001   36.0 (12.0, 108.0)   43.0   98.0    87.1    84.1
             *rrs*, *eis* promoter, *tlyA*   32                    31   5    189                   \<0.001   39.0 (14.1, 108.0)   51.0   97.4    86.5    86.0
  Pre- XDR   *gyrA*                          35                    11   48   163                   \<0.001   11.0 (5.1, 23.0)     76.1   77.3    42.2    94.0
             *rrs*                           5                     41   23   188                   \>0.999   1.0 (0.4, 3.0)       11.0   89.1    18.0    82.1
             *gyrA, rrs*                     37                    9    55   156                   \<0.001   12.0 (5.3, 26.0)     80.4   74.0    40.2    95.0
  XDR        *gyrA*, *rrs*, *eis* promoter   26                    2    55   174                   \<0.001   41.1 (9.5, 179.0)    93.0   76.0    32.1    99.0

a

FQ, fluoroquinolones; SLID, second-line injectable drugs; Pre-XDR, pre-extensively drug-resistant; XDR, extensively drug-resistant.

b

OR, odd ratio; CI, confidence interval.

c

PPV, positive predictive value; NPV, negative predictive value.

On the other side, we observed that 28.6% (18/63), 17.5% (11/63), and 12.7% (8/63) of resistant isolates with an A1401G mutation in *rrs* were resistant to KAN, AMK, and CAP, respectively. Also, we found *rrs* mutations were significantly associated with the cross-resistance of SLID (3.2 *OR*, *95%CI* \[2.2, 4.6\], *P* = 0.002), SLID (29.2 *OR*, *95%CI* \[9.6, 89.0\], *P* \< 0.001), MDR (5.1 *OR*, *95%CI* \[2.0, 13.0\], *P* \< 0.001), and XDR (24.1 *OR*, *95%CI* \[9.4, 62.2\], *P* \< 0.001) ([Figure 2D](#F2){ref-type="fig"}). Moreover, the isolates with *eis* promoter or *tlyA* gene mutations were related to the drug resistance to SLID (16.6 *OR*, *95%CI* \[1.9, 145.3\], *P* = 0.004; 1.0 *OR*, *95%CI* \[0.9, 1.0\], *P* = 0.014, respectively) ([Table 4](#T4){ref-type="table"}). [Table 4](#T4){ref-type="table"} showed the sensitivity and specificity for evaluating phenotypes. For FQ^r^, mutations in *gyrA* and *gyrB* had a combined sensitivity of 79.4% (*95%CI* \[69.7, 86.7\]), and specificity of 89.4% (*95%CI* \[83.3, 93.5\]). For SLID^r^, *rrs* mutations were predicted phenotypes with 38.1% (*95%CI* \[26.4, 51.2\]) sensitivity, and 97.9% (*95%CI* \[94.5, 99.3\]) specificity. When adding the *eis* promoter and *tlyA* mutations, a combined sensitivity of 50.8% (*95%CI* \[38.0, 63.5\]), specificity of 97.4% (*95%CI* \[93.8, 99.0\]). The individual *gyrA* mutations for assessing Pre-XDR had sensitivity, and specificity values of 76.1% (*95%CI* \[60.9, 86.9\]), and 77.3% (*95%CI* \[70.9, 82.6\]), respectively, but adding the *rrs* mutations increased the values of sensitivity and for Pre-XDR detection to 80.4% (*95%CI* \[65.6, 90.1\]), and 73.9% (*95%CI* \[67.4, 79.6\]), respectively. A combined mutation of *gyrA*, *rrs* and *eis* promoter achieved the best evaluation for XDR with the sensitivity, and specificity values of 92.9% (*95%CI* \[75.0, 98.8\]), and 73.9% (*95%CI* \[67.4, 79.6\]), respectively.

Genotyping {#S3.SS5}
----------

Three major diverse families were identified among the 124 SLD^r^ isolates, including Beijing, T and H family. Beijing family was the largest sub-lineage with 112 isolates. Nine isolates belonged to the T family, 6 isolates were T1 sublineage, 2 isolates were T2, and 1 isolate was T3. The remaining 3 isolates were identified as H3 sub-lineage.

Comparison of Spoligotyping results with three drug resistance patterns ([Table 5](#T5){ref-type="table"}), 116 isolates were grouped in 4 clusters and 8 isolates had singletons. Of the singletons, 7 isolates were distributed in clades, Beijing (SIT190, 260, and 621), T1 (SIT522 and 1688), T3 (Orphan) and H3 (SIT1908) with FQ-TB or SLID-TB. Only one Pre-XDR isolate was defined as T1 family (SIT520). The predominance of Beijing family (SIT1) contained 109 isolates clone in FQ-TB (71.8%, 89/124), SLID-TB (43.5%, 54/124) and Pre-XDR/XDR-TB group (56.5%, 70/124). Other three clusters, T1 (SIT53), T2 (SIT52) and H3 (SIT268), 2--3 isolates each, were found in Pre-XDR/XDR-TB and/or additional FQ or SLID. No significant associations were found between the genotypes and specific types of resistance ([Supplementary Table S2](#SD1){ref-type="supplementary-material"}). Meanwhile, no significant correlation was observed between any mutation and a Spoligotype family ([Supplementary Table S3](#SD1){ref-type="supplementary-material"} and [Supplementary Figure S2](#SD1){ref-type="supplementary-material"}).

###### 

Spoligotying characterization of FQ-TB, SLID-TB and Pre-XDR/XDR-TB.

  **Clusters**   **No. of isolates**   **Spoligotype description octonary**   **SIT^a^**   **clades**   **FQ-TB^b^ (*n* = 97)**   **SLID-TB^c^ (*n* = 63)**   **Pre-XDR/XDR-TB^d^ (*n* = 74)**
  -------------- --------------------- -------------------------------------- ------------ ------------ ------------------------- --------------------------- ----------------------------------
  Singleton      1                     000000000003731                        190          Beijing      1                         0                           0
                 1                     000000000003171                        260          Beijing      1                         0                           0
                 1                     000000000002771                        621          Beijing      1                         1                           0
                 1                     777777777760571                        520          T1           1                         0                           1
                 1                     777777777760770                        522          T1           0                         1                           0
                 1                     777777403760771                        1688         T1           0                         1                           0
                 1                     577737777760771                        Orphan       T3           1                         1                           0
                 1                     777777776020771                        1908         H3           0                         1                           0
  Cluster        109                   000000000003771                        1            Beijing      89                        54                          70
                 3                     777777777760771                        53           T1           1                         2                           1
                 2                     777777777760731                        52           T2           2                         0                           1
                 2                     777777677720771                        268          H3           0                         2                           1

a

SIT, soligotyping international type.

b

FQ-TB, fluoroquiolones-tuberculosis.

c

SLID-TB, second-line injectable drugs.

d

Pre-XDR, pre-extensively drug-resistant tuberculosis; XDR, extensively drug-resistant tuberculosis.

A total of 124 SLD^r^ isolates were genotyped by 15-loci MIRU-VNTR, revealed that the strains were divided into 113 genotypes, of which 107 were identified as unique patterns and 17 isolates were categorized to cluster patterns ([Figure 4](#F4){ref-type="fig"}). Six small clusters ranging from 2 to 4 isolates were observed in all genotypes. The cumulative clustering rate and recent transmission rate rely on the MIRU-VNTR typing was 13.7% (17/124) and 4.8% (6/124), respectively.

![An UPGMA-tree based on 15-loci MIRU-VNTR of the clinical 124 *M. tuberculosis* isolates resistant to second-line drugs. From left to right: **(A)** Spoligotype octonary; **(B)** Spoligotype international type (SIT); **(C)** Spoligotype clade; **(D)** 15-loci MIRU-VNTR profile; **(E)** mutational pattern; **(F)** second-line drugs resistance pattern.](fmicb-10-01838-g004){#F4}

Among six clusters with SLD^r^ strains, two Pre-XDR isolates with a *gyrA* (A90V or D94G) mutation occurred exclusively in Cluster I. Cluster II contained three isolates, two Pre-XDR isolates presented at *gyrA* mutation (D94G), one of them accompanied with a mutation at *rrs* (T1491C), the rest of FQ had no mutation. Cluster III grouped in 4 isolates, the Pre-XDR included 2 isolates with a mutation at *gyrA* (D94G or D94A), one was FQ and another was SLID without any mutation. Three isolates of cluster IV had three different polymorphisms at either *gyrA* (A90V or D94N) or *rrs* (A1401G) locus. Cluster V comprised 3 isolates, the XDR had *gyrA* (A90V or D94G) and *rrs* (A1401G) mutations sharing with 2 isolates, whereas one Pre-XDR isolate with *gyrA* (D94G) and *eis* promoter C (−14) T. Cluster VI had one XDR isolate with a mutation at *rrs* (A1401G) and FQ with a mutation at *gyrA* (D94G).

Discussion {#S4}
==========

To our best knowledge, the present study is the first to provide a description of mutations associated with SLD^r^ in *M. tuberculosis* strains from Hebei. Nevertheless, we examined the phylogenetic diversity in SLD^r^ strains through genotyping profiles. The present findings revealed that 48.2% (124/257) were resistant to at least one five SLD. Previously, several studies reported the resistance rate of SLD strains has been estimated to range from 25.7 to 51.9% ([@B4]; [@B8]; [@B17]). According to a recently published World Health Organization (WHO) report, among cases of MDR-TB in 2017, 8.5% (*95%CI*, 6.2--11.0%) were estimated to have XDR-TB ([@B35]). We reported the frequency of XDR-TB is 10.9%.

FQ^r^ isolates is primarily attributed to mutations in the QRDR of *gyrA*. According to a systematic review, *gyrA* mutations were reported in codons 88--94 appeared to account for roughly 60.0--90.0% of FQ^r^ globally ([@B3]). In our present study, mutations at *gyrA* codon 89, 90, 91, and 94 were observed in 75.3% of resistant isolates. The frequency of mutations conferring FQ^r^ is similar to Shanghai (76.0%), although it is lower than those in Russia (83.0%), India (81.0%) and Thailand (92.3%), and higher than those in Morocco (30.0%) and New York (67.0%) ([@B30]; [@B24]; [@B39]; [@B13]; [@B29]; [@B10]), indicating that mutations in *gyrA* tend to differ by geographic region. In line with previous studies ([@B29]; [@B28]; [@B11]), substitutions at codon 94 were the most frequent mutation among FQ^r^ isolates. This phenomenon may be explained by the fact that codon 94, which aims at the water-magnesium ion bridge with a conserved C3/C4 keto acid moiety of quinolones, plays an important role in stabilizing the quinolone molecule in the quinolone binding pocket, an amino acid substitution at this position will exaggerate the deleterious effect of the binding between most quinolones and DNA gyrase ([@B2]; [@B6]; [@B13]).

Interestingly, significant evidence has demonstrated a link between *gyrA* mutations and FQ, MDR, Pre-XDR and XDR, suggesting that mutations at *gyrA* might be act as a candidate diagnostic marker for FQ, MDR and a possible indicator of Pre-XDR-TB or XDR-TB. In *Mycobacterium*, the interactive effect between rifampicin- and FQ-resistant mutations was influenced by epistasis and produced a varying degree of loss in fitness ([@B7]). We hypothesized that the progression of MDR to Pre-XDR or XDR may be caused by the positive epistasis between *gyrA* mutations and mutations in drug resistant gene conferring rifampicin. Certainly, further research is required to confirm this hypothesis.

Unlike the high frequency of *gyrA* mutations, mutations in *gyrB* gene are seldom commonly associated with FQ^r^ in *M. tuberculosis* isolates. A *gyrB* mutation (L442L, S447F, N499T, A504V, or A508A) was identified in 7 FQ^r^ isolates. As far as we known, a L442L, S447F, N499T, A504V mutation has not been previously reported. Due to the small numbers of isolates with *gyrB* mutations, no such mutation was significant independently associated with FQ^r^. Additionally, we found that both FQ^r^ and FQ^s^ strains exhibited an A508A mutation in *gyrB*, making it difficult to acknowledge the contribution to phenotypic resistance. Several publications reported double mutations in *gyrA*, *gyrB* or both *gyrA* and *gyrB*, which ranged from 1.0 to 3.0% ([@B3]; [@B12]; [@B19]). Double mutations in both *gyrA* and *gyrB* were found in FQ^r^ isolates but the absence of susceptible isolates, suggesting that although rare, it can be as the highly specific predictor of FQ^r^.

Previous reports indicated the A1401G in *rrs* effectively identify the phenotypic resistance to KAN, AMK and CAP ([@B23]; [@B32]). In our study, 36.5, 63.2, and 50.0% of sensitivities with an A1401G mutation in *rrs* were resistant to KAN, AMK, and CAP, respectively ([Supplementary Tables S6--S8](#SD1){ref-type="supplementary-material"}). Compared to DST test, it seems that a mutation at A1401G provided a better maker for AMK and CAP than for KAN. However, the canonical A1401G *rrs* mutation explains only around 56.0% of KAN^r^, while the mutations G10A and C14T in the promoter of *eis*, explain another 33.0% of low-level KAN^r^ as estimated by one review ([@B16]). Our study supports these finding, as 5 KAN^r^ isolates were found to have mutations in *eis* promoter, including three of G (−10) A and two of C (−14) T. Mutations in *tlyA* is also known to responsible for resistance to CAP. In fact, we observed three isolates were resistance to CAP alone, but KAN-sensitive and AMK-sensitive isolates had no mutations in *tlyA* gene. Consequently, *tlyA* should be included in the molecular analysis of CAP-resistance.

In our study, *rrs* mutations were significantly associated with MDR-TB (5.1 *OR*, *95%CI* \[2.0, 13.0\], *P* \< 0.001), and XDR-TB (24.1 *OR*, *95%CI* \[9.4, 62.2\], *P* \< 0.001), suggesting the detection of *rrs* mutations provide the valuable information to support the initiation of effective treatment regimens for MDR-TB or even XDR-TB cases. Specifically, as previously reported ([@B37]; [@B26]), we observed a significant cross-resistance between KAN, AMK and CAP associated with *rrs* gene. Therefore, *rrs* might serve as a marker to predict the cross-resistance among SLID agents.

The traditional phenotypic DSTs lead serious delays to the detection of resistance just because of the extremely slow growth of *M. tuberculosis*. However, several commercial diagnostic tests such as GeneXpert MTB/RIF, Genotype MTBDRplus/MTBDRsl assays, have been developed to rapidly detect both first- and second-line drug resistance in *M. tuberculosis* by scanning the associated mutations ([@B36]; [@B20]). Our performance showed that analysis of the associated mutations was recommended to provide a good sensitivity for rapid verification of FQ^r^ (79.4%), SLID^r^ (50.8%), Pre-XDR (80.4%), and XDR (92.9%). In addition, sensitivities and specificities for predicting phenotypic resistance to five SLD in *M. tuberculosis* isolates as shown in [Supplementary Tables S4--S8](#SD1){ref-type="supplementary-material"}.

Spoligotyping result showed that the predominance of Beijing family (SIT1), which accounted for the largest cluster (71.8%) among SLD^r^ strains in this study. No significant associations were found between the genotypes and specific types of resistance. But a high frequency of Beijing family strains among FQ^r^ isolates was previously reported from Vietnam and Russia ([@B24]; [@B14]). One possibility is that the Beijing family strains have a high level of intrinsic resistance to FQ, providing an opportunity to tolerate low level of FQ and subsequently generate *gyrA* mutations, or that these mutations confer an advantage under the absence of antibiotics pressure ([@B24]). An observation revealed that *eis* mutations were considered to be associated with the Beijing clades ([@B9]); however, this is not applicable for all geographical settings. Generally, we found no significant correlation between any mutation and a spoligotype family, which is accordance with reports from China ([@B38], [@B37]).

In this study, an UPGMA-tree was generated from 15-loci MIRU-VNTR among 124 SLD^r^ isolates, which was slightly similar with our previous study on the acquired resistance of MDR-TB in this region ([@B21]). The highly different genotypic patterns and drug resistance profiles suggest that acquisition of resistance is also an important cause for the emergence of SLD^r^ in Hebei Province. MIRU-VNTR data revealed a moderate level of genotypic diversity, which implicated composite mechanisms of resistance, including transmitted and acquired resistance, as a potential cause for the emergence of SLD^r^ strains. Transmission of clustered SLD^r^ strains with identical mutations may indicated the acquisition of drug resistance typically confers a reduction in fitness cost, and mutations may further contribute to the spreading of Pre-XDR-TB or XDR-TB. Therefore, the strict DOTS is the necessary principle to reduce the incidence of acquired strains. In addition, 28.6% of XDR strains were clustered, and it can be inferred that there exists cloning transmission between a small number of XDR strains.

The main limitation of this study was only ability to perform at critical concentrations for DST but not established MICs. This discrepancy of the critical-concentration method used for DST, such that up to 5% of wild-type *M. tuberculosis* strains are classified as drug resistant. While our study is also limited by the number of strains, further studies continue to collect larger additional strains to depict acquired resistance in the community and household and build transmission chain.

Conclusion {#S5}
==========

In summary, this study showed that 48.2% of isolates were resistance to at least one of five SLD, and most of which were resistant to OFX, LVX, and KAN. The majority of FQ^r^ and SLID^r^ strains were associated with *gyrA* mutation at D94G and *rrs* mutation at A1401G, respectively. Mutations in *gyrA*, *rrs*, and *eis* promoter seem to be the causative biomarker for the screening of resistance to SLD, even XDR-TB itself. No correlation was found between any mutation and a spoligotype family. Furthermore, acquired resistance is one of the critical factors driving the SLD^r^ strains in Hebei Province. These results highlight the use of appropriate treatment regimens and the development of early rapid diagnosis are the effective manners for the control of SLD-TB or XDR-TB patients.
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AMK

:   amikacin

CAP

:   capreomycin

CI

:   confidence interval

DOTS

:   directly observed treatment short course

DR-TB

:   drug-resistant tuberculosis
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:   drug susceptibility testing

FQ

:   fluoroquinolones

KAN

:   kanamycin

L-J

:   Lowenstein-Jensen

LVX
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MDR-TB

:   multidrug-resistant tuberculosis

MIC

:   minimum inhibitory concentration

MIRU-VNTR

:   mycobacterial interspersed repetitive unit--variable number of tandem repeats

*M. tuberculosis*

:   *Mycobacterium tuberculosis*

NPV

:   negative predictive value

OFX

:   ofloxacin

OR

:   odd ratio

PCR

:   polymerase chain reaction

PPV

:   positive predictive value

Pre-XDR

:   pre-extensively drug-resistant tuberculosis

QRDR

:   fluoroquinolone resistance-determining region

SIT

:   spoligotyping international type

SLD

:   second-line anti-tuberculosis drugs

SLID

:   second-line injectable drugs

SPSS

:   statistical package for the social sciences

TB

:   tuberculosis

XDR-TB

:   extensively drug-resistant tuberculosis

UPGMA

:   unweighted pair group method with arithmetic mean
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:   world health organization.
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